LIR 生命科学组织与Neuland Labs合作,利用细胞穿透浸泡物开发非注射性补丁型肥胖症治疗,并辅之以230 000美元的第一阶段预算。 LIR Life Sciences partners with Neuland Labs to develop non-injectable, patch-based obesity treatment using cell-penetrating peptides, backed by a $230,000 Phase 1 budget.

LIR生命科学与Neuland实验室合作，开发细胞穿透肽，用于其透皮GLP-1/GIP肥胖治疗平台，第一阶段预算为23万美元。 LIR Life Sciences has partnered with Neuland Laboratories to develop cell-penetrating peptides for its transdermal GLP-1/GIP obesity treatment platform, with a $230,000 Phase 1 budget. 这项合作是根据CGMP标准和林业发展局核准的设施进行的,将支助临床前测试和今后的临床规划。 The collaboration, conducted under cGMP standards and FDA-approved facilities, will support preclinical testing and future clinical planning. LIR旨在利用补丁疗法,创造负担得起的、非注射式疗法。 LIR aims to create affordable, non-injectable therapies using patch-based delivery. 该公司还雇用了Fairfax Partners公司进行150 000美元的数字营销活动,以支持投资者外联工作。 The company also hired Fairfax Partners for a $150,000 digital marketing campaign to support investor outreach.